OTCMKTS:TEAR - TearLab Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0880 0.00 (0.00 %)
(As of 04/26/2019 11:43 AM ET)
Previous Close$0.0880
Today's Range$0.0880 - $0.0880
52-Week Range$0.03 - $0.2550
Volume215 shs
Average Volume26,408 shs
Market Capitalization$1.03 million
P/E RatioN/A
Dividend YieldN/A
TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.

Receive TEAR News and Ratings via Email

Sign-up to receive the latest news and ratings for TEAR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:TEAR
Previous SymbolNASDAQ:TEAR



Sales & Book Value

Annual Sales$25 million
Book Value($1.83) per share


Net Income$-2,250,000.00


Market Cap$1.03 million
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable

TearLab (OTCMKTS:TEAR) Frequently Asked Questions

What is TearLab's stock symbol?

TearLab trades on the OTCMKTS under the ticker symbol "TEAR."

When did TearLab's stock split? How did TearLab's stock split work?

TearLab's stock reverse split on the morning of Friday, February 24th 2017. The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 23rd 2017. An investor that had 100 shares of TearLab stock prior to the reverse split would have 10 shares after the split.

How were TearLab's earnings last quarter?

TearLab Corp (OTCMKTS:TEAR) issued its quarterly earnings results on Thursday, March, 21st. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. The medical research company earned $5.99 million during the quarter. View TearLab's Earnings History.

When is TearLab's next earnings date?

TearLab is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for TearLab.

Has TearLab been receiving favorable news coverage?

Headlines about TEAR stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TearLab earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days.

Who are some of TearLab's key competitors?

What other stocks do shareholders of TearLab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TearLab investors own include Vertex Energy (VTNR), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX), Immunomedics (IMMU), Verastem (VSTM), Biocept (BIOC), Corbus Pharmaceuticals (CRBP), Omeros (OMER) and Sophiris Bio (SPHS).

Who are TearLab's key executives?

TearLab's management team includes the folowing people:
  • Mr. Elias Vamvakas, Exec. Chairman & Sec. (Age 60)
  • Mr. Joseph S. Jensen, CEO & Director (Age 47)
  • Mr. Michael Marquez, Chief Financial Officer (Age 37)
  • Dr. Benjamin Sullivan Ph.D., Chief Scientific Officer (Age 43)
  • Mr. Sam Fakhoury, VP of Quality, Compliance & Supply Chain

How do I buy shares of TearLab?

Shares of TEAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TearLab's stock price today?

One share of TEAR stock can currently be purchased for approximately $0.0880.

How big of a company is TearLab?

TearLab has a market capitalization of $1.03 million and generates $25 million in revenue each year. TearLab employs 34 workers across the globe.

What is TearLab's official website?

The official website for TearLab is http://www.tearlab.com.

How can I contact TearLab?

TearLab's mailing address is 150 La Terraza Blvd. Suite 101, Escondido CA, 92025. The medical research company can be reached via phone at 858-455-6006 or via email at [email protected]

MarketBeat Community Rating for TearLab (OTCMKTS TEAR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  533
MarketBeat's community ratings are surveys of what our community members think about TearLab and other stocks. Vote "Outperform" if you believe TEAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel